

Philip N Hawkins

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5738097/publications.pdf>

Version: 2024-02-01

107
papers

13,984
citations

57631

44
h-index

38300

95
g-index

111
all docs

111
docs citations

111
times ranked

8965
citing authors

#	ARTICLE	IF	CITATIONS
1	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. <i>Circulation</i> , 2016, 133, 2404-2412.	1.6	1,335
2	Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. <i>American Journal of Hematology</i> , 2005, 79, 319-328.	2.0	1,179
3	Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. <i>Nature</i> , 1997, 385, 787-793.	13.7	1,061
4	New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes. <i>Journal of Clinical Oncology</i> , 2012, 30, 4541-4549.	0.8	735
5	Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. <i>Arthritis and Rheumatism</i> , 2004, 50, 607-612.	6.7	731
6	Systemic amyloidosis. <i>Lancet</i> , The, 2016, 387, 2641-2654.	6.3	703
7	Misdiagnosis of Hereditary Amyloidosis as AL (Primary) Amyloidosis. <i>New England Journal of Medicine</i> , 2002, 346, 1786-1791.	13.9	621
8	Evaluation of Systemic Amyloidosis by Scintigraphy with ¹²³ I-Labeled Serum Amyloid P Component. <i>New England Journal of Medicine</i> , 1990, 323, 508-513.	13.9	497
9	Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. <i>Circulation</i> , 2015, 132, 1570-1579.	1.6	442
10	EULAR recommendations for the management of familial Mediterranean fever. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 644-651.	0.5	393
11	A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. <i>Blood</i> , 2013, 121, 3420-3427.	0.6	385
12	Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP ^{met30}). <i>Clinical Genetics</i> , 1991, 40, 242-246.	1.0	350
13	Systemic immunoglobulin light chain amyloidosis. <i>Nature Reviews Disease Primers</i> , 2018, 4, 38.	18.1	350
14	Native T1 Mapping in Transthyretin Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 157-165.	2.3	339
15	A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. <i>Blood</i> , 2015, 126, 612-615.	0.6	334
16	T1 mapping and survival in systemic light-chain amyloidosis. <i>European Heart Journal</i> , 2015, 36, 244-251.	1.0	310
17	Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. <i>New England Journal of Medicine</i> , 2015, 373, 1106-1114.	13.9	304
18	Magnetic Resonance in Transthyretin Cardiac Amyloidosis. <i>Journal of the American College of Cardiology</i> , 2017, 70, 466-477.	1.2	290

#	ARTICLE	IF	CITATIONS
19	CMR-Based Differentiation of AL and ATTR Cardiac Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 133-142.	2.3	242
20	Online Registry for Mutations in Hereditary Amyloidosis Including Nomenclature Recommendations. <i>Human Mutation</i> , 2014, 35, E2403-E2412.	1.1	220
21	Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. <i>British Journal of Haematology</i> , 2000, 110, 454-460.	1.2	192
22	Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 1289-1298.	0.5	184
23	Native T1 and Extracellular Volume in β -Transthyretin Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 810-819.	2.3	172
24	AMYLOIDOSIS: A REVIEW OF RECENT DIAGNOSTIC AND THERAPEUTIC DEVELOPMENTS. <i>British Journal of Haematology</i> , 1997, 99, 245-256.	1.2	166
25	Automated Pixel-Wise Quantitative Myocardial Perfusion Mapping by CMR to Detect Obstructive Coronary Artery Disease and Coronary Microvascular Dysfunction. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 1958-1969.	2.3	140
26	Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. <i>Current Opinion in Nephrology and Hypertension</i> , 2002, 11, 649-655.	1.0	132
27	A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. <i>Blood</i> , 2019, 134, 2271-2280.	0.6	130
28	Diagnostic Performance of ^{123}I -Labeled Serum Amyloid P Component Scintigraphy in Patients with Amyloidosis. <i>American Journal of Medicine</i> , 2006, 119, 355.e15-355.e24.	0.6	129
29	Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). <i>Haematologica</i> , 2014, 99, 1479-1485.	1.7	118
30	Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 823-833.	2.3	113
31	Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. <i>European Heart Journal</i> , 2020, 41, 1439-1447.	1.0	108
32	Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study. <i>Lancet Haematology</i> , 2015, 2, e241-e250.	2.2	105
33	SAA ₁ alleles as risk factors in reactive systemic AA amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 1998, 5, 262-265.	1.4	104
34	Systemic amyloidosis. <i>Current Opinion in Pharmacology</i> , 2006, 6, 214-220.	1.7	102
35	Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. <i>British Journal of Haematology</i> , 2006, 134, 417-425.	1.2	84
36	International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. <i>Rheumatology</i> , 2017, 56, 2102-2108.	0.9	84

#	ARTICLE	IF	CITATIONS
37	Diagnostic imaging of cardiac amyloidosis. <i>Nature Reviews Cardiology</i> , 2020, 17, 413-426.	6.1	84
38	Studies with Radiolabelled Serum Amyloid P Component Provide Evidence for Turnover and Regression of Amyloid Deposits <i>In Vivo</i>. <i>Clinical Science</i> , 1994, 87, 289-295.	1.8	75
39	Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1998, 25, 709-713.	3.3	68
40	European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin Mâ€‘Related Light Chain Amyloidosis. <i>Journal of Clinical Oncology</i> , 2016, 34, 2037-2045.	0.8	60
41	Allogeneic bone marrow transplantation for systemic AL amyloidosis. <i>British Journal of Haematology</i> , 1998, 100, 226-228.	1.2	51
42	Measurement of Tissue Interstitial Volume in Healthy Patients and Those with Amyloidosis with Equilibrium Contrast-enhanced MR Imaging. <i>Radiology</i> , 2013, 268, 858-864.	3.6	49
43	Autosomal dominant familial Mediterranean fever in Northern European Caucasians associated with deletion of p.M694 residueâ€‘a case series and genetic exploration. <i>Rheumatology</i> , 2017, 56, 209-213.	0.9	49
44	An autosomal dominant periodic fever associated with AA amyloidosis in a North Indian family maps to distal chromosome 1q. <i>Arthritis and Rheumatism</i> , 2000, 43, 2034-2040.	6.7	48
45	Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis. <i>European Heart Journal</i> , 2022, 43, 333-341.	1.0	45
46	Assessment of Multivessel Coronary Artery Disease Using Cardiovascular Magnetic Resonance Pixelwise Quantitative Perfusion Mapping. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 2546-2557.	2.3	30
47	A case series and systematic literature review of anakinra and immunosuppression in idiopathic recurrent pericarditis. <i>Journal of Cardiology Cases</i> , 2011, 4, e93-e97.	0.2	29
48	Hereditary systemic amyloidosis with renal involvement. <i>Journal of Nephrology</i> , 2003, 16, 443-8.	0.9	29
49	Acute changes in cardiac structural and tissue characterisation parameters following haemodialysis measured using cardiovascular magnetic resonance. <i>Scientific Reports</i> , 2019, 9, 1388.	1.6	27
50	Characteristics and natural history of early-stage cardiac transthyretin amyloidosis. <i>European Heart Journal</i> , 2022, 43, 2622-2632.	1.0	27
51	^{99m} Tc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 1304-1311.	0.5	26
52	ALchemy - A Large Prospective â€‘Real World' Study of Chemotherapy in AL Amyloidosis. <i>Blood</i> , 2011, 118, 992-992.	0.6	26
53	Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis. <i>European Journal of Heart Failure</i> , 2022, 24, 1700-1712.	2.9	26
54	Emerging treatments for amyloidosis. <i>Kidney International</i> , 2015, 87, 516-526.	2.6	25

#	ARTICLE	IF	CITATIONS
55	A European Collaborative Study of Treatment Outcomes In 428 Patients with Systemic AL Amyloidosis. <i>Blood</i> , 2010, 116, 988-988.	0.6	25
56	Two types of amyloid in a single heart. <i>Blood</i> , 2014, 124, 3025-3027.	0.6	24
57	Noninvasive Mapping of the Electrophysiological Substrate in Cardiac Amyloidosis and Its Relationship to Structural Abnormalities. <i>Journal of the American Heart Association</i> , 2019, 8, e012097.	1.6	21
58	Cardiac Magnetic Resonanceâ€“Derived Extracellular Volume Mapping for the Quantification of Hepatic and Splenic Amyloid. <i>Circulation: Cardiovascular Imaging</i> , 2021, 14, CIRCIMAGING121012506.	1.3	19
59	Validation of the Criteria of Response to Treatment In AL Amyloidosis.. <i>Blood</i> , 2010, 116, 1364-1364.	0.6	19
60	Quantitative cardiovascular magnetic resonance myocardial perfusion mapping to assess hyperaemic response to adenosine stress. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 273-281.	0.5	15
61	Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting. <i>Haematologica</i> , 2014, 99, e260-e263.	1.7	14
62	Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance. <i>Leukemia</i> , 2020, 34, 1187-1191.	3.3	13
63	Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Versus Melphalan Plus Dexamethasone (MD) for Newly-Diagnosed Systemic AL Amyloidosis â€“ Results From the UK Amyloidosis Treatment Trial.. <i>Blood</i> , 2009, 114, 2869-2869.	0.6	13
64	001â€“...Multiparametric mapping to understand pathophysiology in cardiac amyloidosis. <i>Heart</i> , 2017, 103, A1-A2.	1.2	12
65	Efficacy and Safety of Bortezomib in Systemic AL Amyloidosis - A Preliminary Report.. <i>Blood</i> , 2006, 108, 129-129.	0.6	11
66	TRAP1 chaperone protein mutations and autoinflammation. <i>Life Science Alliance</i> , 2020, 3, e201900376.	1.3	9
67	Comparison of Free Light Chain Assays. <i>American Journal of Clinical Pathology</i> , 2016, 146, 78-85.	0.4	8
68	Apolipoprotein E4 genotype is not a risk factor for systemic AA amyloidosis or familial amyloid polyneuropathy. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 1995, 2, 163-166.	1.4	7
69	Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts. <i>Haematologica</i> , 2017, 102, e411-e414.	1.7	7
70	Intermediate Dose Intravenous Melphalan and Dexamethasone Treatment in 144 Patients with Systemic AL Amyloidosis.. <i>Blood</i> , 2004, 104, 755-755.	0.6	7
71	Role of NT-ProBNP to Assess the Adequacy of Treatment Response in AL Amyloidosis.. <i>Blood</i> , 2008, 112, 1689-1689.	0.6	7
72	Role of ^{99m} Tcâ€“DPD scintigraphy in imaging extraâ€“cardiac light chain (AL) amyloidosis. <i>British Journal of Haematology</i> , 2018, 183, 506-509.	1.2	6

#	ARTICLE	IF	CITATIONS
73	Two types of systemic amyloidosis in a single patient. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 275-276.	1.4	6
74	Significant Activity of Bortezomib-Based Therapy in Patients with Primary Systemic (AL) Amyloidosis. <i>Blood</i> , 2008, 112, 869-869.	0.6	6
75	A New Staging System for AL Amyloidosis Incorporating Serum Free Light Chains, cardiac Troponin-T and NT-ProBNP.. <i>Blood</i> , 2009, 114, 2796-2796.	0.6	6
76	In AL Amyloidosis, Both Oral Melphalan and Dexamethasone (Mel-Dex) and Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Have Similar Efficacy as Upfront Treatment.. <i>Blood</i> , 2009, 114, 745-745.	0.6	6
77	High prevalence of recurrent nocturnal desaturations in systemic AL amyloidosis: a cross-sectional pilot study. <i>Sleep Medicine</i> , 2017, 32, 191-197.	0.8	5
78	Search for AL amyloidosis risk factors using Mendelian randomization. <i>Blood Advances</i> , 2021, 5, 2725-2731.	2.5	5
79	European Collaborative Study of Treatment Outcomes in 347 Patients with Systemic AL Amyloidosis with Mayo Stage III Disease. <i>Blood</i> , 2011, 118, 995-995.	0.6	5
80	Six-minute walk test (6MWT) in AL amyloidosis – baseline and 12-month follow-up after chemotherapy. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 62-63.	1.4	4
81	Recognising and understanding cryopyrin-associated periodic syndrome in adults. <i>British Journal of Nursing</i> , 2019, 28, 1180-1186.	0.3	4
82	Transient Post Chemotherapy Rise in NT Pro-BNP in AL Amyloidosis : Implications for Organ Response Assessment.. <i>Blood</i> , 2009, 114, 1791-1791.	0.6	4
83	A good clonal response to chemotherapy in AL amyloidosis is associated with improved quality of life and function at 1 year. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 72-73.	1.4	3
84	The UK National Amyloidosis Centre. <i>European Heart Journal</i> , 2019, 40, 1661-1664.	1.0	3
85	Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) for the Treatment of Systemic AL Amyloidosis: Long Term Outcomes among 202 Patients.. <i>Blood</i> , 2008, 112, 1733-1733.	0.6	3
86	Acute Hepatitis in a Child Heterozygous for the I259V MEFV Gene Variant. <i>Prague Medical Report</i> , 2014, 115, 128-133.	0.4	3
87	Hyperimmunoglobulin D syndrome in an Indian family undiagnosed for 11 years. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 2236-2237.	0.9	2
88	Standard Oral Melphalan Chemotherapy for AL Amyloidosis Revisited Using the Serum Free Light Chain Assay.. <i>Blood</i> , 2005, 106, 3495-3495.	0.6	2
89	A Matched Comparison of Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in the Treatment of Mayo Cardiac Stage III Patients with AL Amyloidosis.. <i>Blood</i> , 2012, 120, 2966-2966.	0.6	2
90	The Prognostic Significance of Phenotypically –Normal– Plasma Cells in Chemotherapy Treated AL Patients with Underlying MGUS and Multiple Myeloma. <i>Blood</i> , 2014, 124, 2073-2073.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Complete and Very Good Partial Responses Are Attainable Endpoints in Elderly Patients (>75 years) with AL Amyloidosis and Are Associated with Improved Overall Survival,. Blood, 2011, 118, 3975-3975.	0.6	1
92	Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Therapy in AL Amyloidosis Is Associated with High Clonal Response Rates and Prolonged Progression Free Survival,. Blood, 2011, 118, 3978-3978.	0.6	1
93	Treatment and Outcome of 267 Patients with IgM-Related AL Amyloidosis. Blood, 2012, 120, 4074-4074.	0.6	1
94	Longterm Outcomes and Improved Renal Function with Autologous Stem Cell Transplantation (ASCT) in Light Chain Deposition Disease (LCDD). Blood, 2014, 124, 1198-1198.	0.6	1
95	The Impact of Longitudinal Strain on Haematological and Cardiac Response and Survival in Patients with Systemic AL Amyloidosis. Blood, 2020, 136, 40-40.	0.6	1
96	Panda eyes and heart failure. British Journal of Hospital Medicine (London, England: 2005), 2005, 66, 700-701.	0.2	0
97	05â€œfAdult Periodic Fevers, Aphthous Ulceration, Pharyngitis and Adenitis: A Single-Centre Experience. Rheumatology, 2016, , .	0.9	0
98	3â€œ...Treatment response in cardiac al amyloidosis assessed by CMR: findings at 3 months, 6 months and 1 year post-chemotherapy. , 2018, , .		0
99	AB0901â€œ...TWO TYPES OF SYSTEMIC AMYLOIDOSIS IN A SINGLE PATIENT. , 2019, , .		0
100	19â€œ...Myocardial perfusion mapping in cardiac amyloidosis- unearthing the spectrum from infiltration to ischaemia. , 2019, , .		0
101	21â€œ...Intracardiac thrombi in cardiac amyloidosis, a common finding. , 2019, , .		0
102	Impact of Chromosomal Abnormalities Revealed by Interphase FISH on Survival in Primary Light Chain Amyloidosis.. Blood, 2004, 104, 4875-4875.	0.6	0
103	Early Detection of Cardiac Systolic Functional Impairment and Correlation with NT-ProBNP Change in AL Amyloidosis by Cardiac Lateral Wall Tissue Doppler S Wave.. Blood, 2009, 114, 2814-2814.	0.6	0
104	Is There a Role for Thalidomide Maintenance in the Treatment of AL Amyloidosis?.. Blood, 2009, 114, 1863-1863.	0.6	0
105	Remarkable Efficacy of IL-1 Receptor Antagonist In Schnitzler's Syndrome: a Series of 6 Cases. Blood, 2010, 116, 3958-3958.	0.6	0
106	Continuous Therapy with Lenalidomide Correlates with Improved Progression Free Survival in Heavily Pre-Treated Patients with AL Amyloidosis.. Blood, 2012, 120, 2978-2978.	0.6	0
107	A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with Systemic AL Amyloidosis. Blood, 2014, 124, 305-305.	0.6	0